Merck to develop USD 1.3 billion research center in London by 2025
By Nikita Chaurasia  Date: 2020-08-19

Merck to develop USD 1.3 billion research center in London by 2025

America-based leading pharmaceutical company Merck & Co. Inc. (MSD) is reportedly moving ahead with its plans of building a research center in London. Sources close to the matter stated that the new facility, which will be known as London Discovery Research Centre, is valued at USD 1.3 billion and is estimated to be operational by the year 2025.

The project was initially announced in 2017 as a part of Merck’s initiative to support Britain post-Brexit, although it was delayed owing to the limitations in finding adequate space in the city, sources claimed. In addition to this, Merck intends to build its life sciences center near the Francis Crick Institute in the northern part of London.

However, the deal is yet to be finalized since it apparently requires the approval of London Borough of Camden. If sources are to be believed, work on the research center is anticipated to start late in 2021, with the facility providing over 120 jobs for technicians as well as researchers.

It appears that the site will be around 25,000 square meters and Merck intends to hire around 800 staff. Sources further stated that the research teams at the site will conduct early-stage diagnostics and majorly focus on age-related disorders.

MSD Managing Director for Ireland and UK, David Peacock, was reported saying that the company views the United Kingdom as a leader in developing science, which is primarily driven by the country’s long-term focus on developing a robust R&D infrastructure.

It is to be noted that Merck had entered a five-year joint venture agreement with Crick Institute to promote research & development in neuroscience. Although Merck’s research projects were conducted independently, the team was completely integrated into the scientific community of Crick Institute.

In fact, research teams from Merck and Crick collaborated in August 2019, in an effort to analyze the cause of Motore Neurone Disease, which was the first combined project since the initial five-year partnership.

Source Credits –

https://www.biospace.com/article/merck-to-build-1-31-billion-research-hub-in-london/

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...